Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 41

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 41
---
 2025 at 2:30 p.m. (GMT) for the purpose of considering and, if thought fit, passing the following Resolution. Shareholders are strongly encouraged to participate in the General Meeting electronically via the online platform by logging on to https://meetings.lumiconnect.com/100-392-363-424 on their personal device. Details on how to participate in the General Meeting can be found in the joining instructions on pages 38 to 39 of this Notice and, for holders of Swedish Listed Shares and AstraZeneca ADSs, in the separate documents sent to them.

Capitalised terms used in this Notice of General Meeting (the

#### “Notice”
) which are not defined herein shall have the meanings ascribed to them in the document of which this Notice forms part.

The Resolution is being proposed as a special resolution.

### SPECIAL RESOLUTION
1.

#### THAT
, the articles of association produced to the meeting (and for the purpose of identification signed by the Chair of the meeting) be adopted as the articles of association of the Company in substitution for and to the exclusion of the existing articles of association of the Company with effect from the conclusion of the meeting.

By order of the Board of Directors of the Company

#### Matthew Bowden
Company Secretary

29 September 2025

Registered office:

AstraZeneca PLC 
 1 Francis Crick Avenue 
 Cambridge Biomedical Campus 
 Cambridge 
 United Kingdom 
 CB2 0AA

Registered in England & Wales No. 02723534

<div align='center'>33</div>

TABLE OF CONTENTS

### Notes to the Notice of General Meeting
Holders of AstraZeneca ADSs

Registered holders of AstraZeneca ADSs will receive a separate proxy voting instruction card and meeting guide, which includes instructions on how to vote and participate in the General Meeting and the remainder of these Notes to the Notice of General Meeting do not apply to such persons.

Holders of AstraZeneca ADSs should therefore follow the voting and other instructions set out in the separate documentation provided to them. AstraZeneca ADS holders are encouraged to vote in advance of the General Meeting through the ADR Depositary, although arrangements will be in place to facilitate voting during the General Meeting. Where AstraZeneca ADS holders have submitted voting instructions in advance, it will not be possible to vote, or change previously submitted voting instructions, during the General Meeting via the online platform. Therefore, any AstraZeneca ADS holder wishing to vote via